Farmakoterapi Penyakit Paru Obstruksi Kronik (PPOK)
DOI:
https://doi.org/10.55175/cdk.v46i4.479Keywords:
Antiinflamasi, bronkodilator, inhalasi, PPOKAbstract
Penyakit Paru Obstruksi Kronik (PPOK) adalah penyakit yang umum, dapat dicegah dan diobati, ditandai dengan gejala pernapasan persisten dan keterbatasan aliran udara yang disebabkan kelainan saluran napas dan/atau alveoli yang biasanya disebabkan oleh paparan signifikan terhadap partikel atau gas berbahaya. Manajemen optimal PPOK multifaset yang menggabungkan strategi non-obat dan manajemen obat. Beberapa obat seperti bronkodilator dan antiinflamasi dapat membantu pasien PPOK.
Chronic Obstructive Pulmonary Disease (COPD) is a common disease, preventable and treatable disease, characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities, usually caused by significant exposure to noxious particles or gas. The optimal management requires a multifaceted approach which incorporates non-drug as well as drug-management strategies. Some medications such as inhalation bronchodilators and anti-inflammatory agents can help COPD patients
Downloads
References
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2018 report) [Internet]. 2018 [cited 2018 Oct 1]. Availablefrom: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf
Young RJ, Murphy KR. Review of the 2009 Global initiative for chronic obstructive lung disease (GOLD) guidelines for the pharmacological management of chronic obstructive pulmonary disease [Internet]. 2009 [cited 2018 Oct 1]. Available from: http://advanceweb.com/web/focus_on_copd/article2.html
PPOK. Diagnosis dan penatalaksanaan. Jakarta: Perhimpunan Dokter Paru Indonesia; 2011.
Swift D. COPD: 3.2 million deaths worldwide in 2015 [Internet]. 2017 [cited 2018 Oct 1] Available from: https://www.medscape.com/viewarticle/884400_print
Soeroto AY, Suryadinata H. Penyakit paru obstruktif kronik. Ina J Chest Crit Emerg Med. 2014;1(2):83-8.
Penyakit paru obstruktif kronik (PPOK). Pedoman diagnosis & penatalaksanaan di Indonesia. Jakarta: Perhimpunan Dokter Paru Indonesia; 2003.
Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE. Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet 1991;336(8728):1396-9.
Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-89.
Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): A double-blind randomised controlled trial. Lancet. 2016;387(10030):1817-26. doi: 10.1016/S0140-6736(16)30069-1.
Yang IA, Clarke MS, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;7(7):CD002991.
Walters JA, Tan DJ, White CJ, Gibson PG, Wood-Baker R, Walters EH. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014;(9):CD001288.
Manson SC, Brown RE, Cerulli A, Vidaurre CF. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med. 2009;103(7):975-94.
Cazzola M, Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23(4):257-67.
Gross N, Tashkin D, Miller R, Oren J, Coleman W, Linberg S. Inhalation by nebulization of albuterolipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group. Respiration 1998; 65(5):354-62.
Tashkin DP, Pearle J, Iezzoni D, Varghese ST. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD 2009;6(1):17-25.
Mahler DA, Kerwin E, Ayers T, FowlerTaylor A, Maitra S, Thach C, et al. FLIGHT1 and FLIGHT2: Efficacy and safety of qva149 (indacaterol/glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015;192(9): 1068-79,
Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016;374(23):2222-34.
Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;9(9): CD006829.
Nannini LJ, Poole P, Milan SJ, Kesterton A. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;8(8):CD006826.
Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-89.
Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): A double-blind randomised controlled trial. Lancet 2016;387(10030):1817-26.
Singh D, Brooks J, Hagan G, Cahn A, O’Connor BJ. Superiority of ”triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008;63(7):592-8.
Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: A randomized trial. Ann Intern Med 2007;146(8):545-55.
Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): A double-blind, parallel group, randomised controlled trial. Lancet 2017; 389(10082):1919-29.
Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, et al. FULFIL Trial: Once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438-46.
Uzun S, Djamin RS, Kluytmans JA, Mulder PG, van’t Veer NE, Ermens AA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): A randomised, doubleblind, placebo-controlled trial. The Lancet Respiratory medicine 2014;2(5):361-8.
Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178(11):1139-47.
Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689-98.
Cazzola M, Calzetta L, Page C, Jardim J, Chuchalin AG, Rogliani P, et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: A meta-analysis. Eur Respir Rev. 2015;24(137):451-61.
Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;(7): CD001287.
Schildmann EK, Remi C, Bausewein C. Levodropropizine in the management of cough associated with cancer or nonmalignant chronic disease--a systematic review. J Pain Palliat Care Pharmacother. 2011;25(3):209-18.
Chapman KR, Stockley RA, Dawkins C, Wilkes MM, Navickis RJ. Augmentation therapy for alpha1 antitrypsin deficiency: A meta-analysis. Copd. 2009; 6(3):177-84.
The alpha-1-antitrypsin deficiency registry study group. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. Am J Respir Crit Care Med. 1998;158(1):49-59.
Stockley RA, Edgar RG, Pillai A, Turner AM. Individualized lung function trends in alpha-1-antitrypsin deficiency: A need for patience in order to provide patient centered management? Int J Chron Obstruct Pulmon Dis. 2016;11:1745-56.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 https://creativecommons.org/licenses/by-nc/4.0/
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
